Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Trial Profile

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2015

At a glance

  • Drugs Peptide hydrolase inhibitors (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 11 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top